CompletedPHASE2, PHASE3NCT02435173
Study of Efficacy of CDZ173 in Patients With APDS/PASLI
Studying Activated PI3K-delta syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Novartis Pharmaceuticals
- Principal Investigator
- Koneti V Rao, MDNational Institutes of Health (NIH)
- Intervention
- CDZ173(drug)
- Enrollment
- 37 enrolled
- Eligibility
- 12-75 years · All sexes
- Timeline
- 2015 – 2021
Study locations (10)
- National Institute of Health NIH, Bethesda, Maryland, United States
- Novartis Investigative Site, Minsk, Belarus
- Novartis Investigative Site, Prague, Czechia
- Novartis Investigative Site, Dresden, Germany
- Novartis Investigative Site, Dublin, Ireland
- Novartis Investigative Site, Palermo, PA, Italy
- Novartis Investigative Site, Brescia, Italy
- Novartis Investigative Site, Rotterdam, Netherlands
- Novartis Investigative Site, Moscow, Russia
- Novartis Investigative Site, Belfast, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02435173 on ClinicalTrials.govOther trials for Activated PI3K-delta syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT06694363New Biomarker-based Strategy to Screen and Monitor for Activated Phosphoinositide 3-kinase δ SyndromeAssistance Publique - Hôpitaux de Paris
- ACTIVE NOT RECRUITINGPHASE3NCT05693129Pediatric Patients Aged 1 to 6 Years With APDSPharming Technologies B.V.
- ACTIVE NOT RECRUITINGPHASE3NCT05438407Pediatric Patients Aged 4 to 11 Years With APDSPharming Technologies B.V.
- RECRUITINGNCT06566872Collecting Recorded Videos of Colonoscopy and Gastroscopy Tests for the Evaluation of the (ME-APDS).Magentiq Eye LTD